T. Mari
7 Papers
115 Citations
T. Mari is an academic researcher. The author has contributed to research in topics: Adefovir & Multicenter trial. The author has an hindex of 4, co-authored 7 publications.
Chat about Author
Papers
Pegylated interferon Alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients
Gloria Taliani,Giulia Gemignani,Carlo Ferrari,Antonio Aceti,Dario Bartolozzi,P.L. Blanc,Marco Capanni,Esperti F,Paolo Forte,Vincenzo Guadagnino,T. Mari,Nicoletta Marino,Stefano Milani,Caterina Pasquazzi,Floriano Rosina,Danilo Tacconi,Mario Toti,Anna Linda Zignego,Luca Messerini,Tommaso Stroffolini +19 more
TL;DR: Retreatment with pegylated IFN-alpha-2b and ribavirin of multi-experienced and "difficult to treat" nonresponder patients produced a very promising virologic response (SVR).
97
A randomized controlled trial of pegylated interferon-α2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B:
Paola Piccolo,Ilaria Lenci,Luigi Demelia,Franco Bandiera,M.R. Piras,Giorgio Antonucci,Lorenzo Nosotti,T. Mari,Adriano De Santis,Maria Laura Ponti,Orazio Sorbello,Fabio Iacomi,Mario Angelico +12 more
TL;DR: In HBeAg-negative CHB, combination PEG-IFN-alpha2a plus ADV for 48 weeks is safe and resulted in greater on-treatment efficacy than PEG/ifN- alpha2a monotherapy.
92
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro
Romina Salpini,Matteo Surdo,Nadia Warner,Maria Francesca Cortese,Danny Colledge,Sally Soppe,Maria Concetta Bellocchi,Daniele Armenia,L. Carioti,Fabio Continenza,Domenico Di Carlo,Patrizia Saccomandi,Carmen Mirabelli,Michela Pollicita,R. Longo,S. Romano,Giuseppina Cappiello,Alberto Spanò,Pascale Trimoulet,Hervé Fleury,Jacopo Vecchiet,N. Iapadre,A. Barlattani,Ada Bertoli,T. Mari,Caterina Pasquazzi,Gabriele Missale,Cesare Sarrecchia,Elisa Orecchini,Alessandro Michienzi,Massimo Andreoni,Simona Francioso,Mario Angelico,Jens Verheyen,Francesca Ceccherini-Silberstein,Stephen Locarnini,Carlo Federico Perno,Valentina Svicher +37 more
TL;DR: Specific mutations in HBsAg C-terminus significantly correlate with HBV-induced HCC and are associated with increased cellular proliferation, supporting their involvement in HCC-development.
[54] PEGINTERFERON-ALPHA-2a PLUS ADEFOVIR VS. PEGINTERFERON ALPHA-2a FOR 48 WEEKS IN HBeAg-NEGATIVE CHRONIC HEPATITIS B: PRELIMINARY 24-WEEK RESULTS OF THE PEG FOR B RANDOMIZED MULTICENTER TRIAL
Paola Piccolo,I. Lend,D. Di Paolo,C. Telesca,Luigi Demelia,Orazio Sorbello,Franco Bandiera,M.R. Piras,G. Antonucci,F. lacomi,Lorenzo Nosotti,T. Mari,A. DeSantis,F. Cristofari,M.L. Ponti,Mario Angelico +15 more
6
256 Peginterferon Alpha-2a Plus Adefovir Dipivoxil vs. Peginterferon Alpha-2a Monotherapy for 48 Weeks in HBeAg-Negative Chronic Hepatitis B: Final Results of the PEG for B Randomized Multicenter Trial
Paola Piccolo,Luigi De Melia,Franco Bandiera,M.R. Piras,Giorgio Antonucci,Lorenzo Nosotti,T. Mari,Adriano De Santis,Laura Ponti,Ilaria Lenci,Daniele Di Paolo,C. Telesca,Orazio Sorbello,Fabio Iacomi,F. Cristofari,Mario Angelico +15 more
3